ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CMPS vs URGN // RETURN ON INVESTED CAPITAL (ROIC)

COMPASS Pathways Plc American Depository Shares (NASDAQ) VS. UroGen Pharma Ltd. (NASDAQ) • 15-METRIC TALLY: CMPS 3 — URGN 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CMPS VS. URGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CMPS URGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 88.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.31% -9.94% +0.63 CMPS /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 21.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 3/9 -2.00 URGN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.1 29.7 +16.40 CMPS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.60B $1.60B $2.8M CMPS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CMPS REV URGN REV CMPS GROSS % URGN GROSS % CMPS FCF URGN FCF
FY 2025 $501.3M $109.8M — 88.7% -$157.2M -$162.7M
FY 2024 $499.0M $90.4M — 90.2% -$119.2M -$97.1M
FY 2023 $383.4M $82.7M — — -$97.4M -$76.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CMPS // BETA —
URGN // BETA —